Variation in hospital resource use and cost among surgical procedures using topical absorbable hemostats

@article{Martyn2015VariationIH,
  title={Variation in hospital resource use and cost among surgical procedures using topical absorbable hemostats},
  author={Derek C. Martyn and Lisa M. Meckley and Gavin S Miyasato and Sangtaeck Lim and Jerome B. Riebman and Richard Kocharian and Jillian G Scaife and Yajing Rao and Mitra Corral},
  journal={ClinicoEconomics and Outcomes Research: CEOR},
  year={2015},
  volume={7},
  pages={567 - 574}
}
Background Adjunctive hemostats are used to assist with the control of intraoperative bleeding. The most common types are flowables, gelatins, thrombins, and oxidized regenerated celluloses (ORCs). In the US, Surgicel® products are the only US Food and Drug Administration-approved ORCs. Objective To compare the outcomes of health care resource utilization (HRU) and costs associated with using ORCs compared to other adjunctive hemostats (OAHs are defined as flowables, gelatins, and topical… 

Figures and Tables from this paper

Cost-effectiveness analysis of a sealing hemostat patch (HEMOPATCH) vs standard of care in cardiac surgery

This analysis supports the use of HEMOPATCH over SOC in cardiac surgery in European hospitals to improve hemostasis success rates and potential cost offsets from reduced transfusions, complications, and surgical revisions.

Topical hemostatic and tissue-sealing agents in gynecologic surgery.

Although evidence exists for the efficacy of THA in reducing blood loss and operating times across surgical subspecialties, specific, appropriate, and efficacious use of THAs in gynecologic surgery remains ill-defined.

Safety and Hemostatic Effectiveness of SURGICEL® Powder (Oxidized Regenerated Cellulose) in Controlling Mild or Moderate Parenchymal or Soft-Tissue Intraoperative Bleeding

This post-market clinical study supports the safety and efficacy of Surgicel®-P in controlling mild-to-moderate surgical bleeding in a broad range of surgical procedures.

Real-world Bleeding Outcomes and Costs Following Vascular Graft Anastomosis Using PROLENE Sutures with HEMO-SEAL Technology in Patients Undergoing Abdominal Aortic Aneurysm Repair

The results indicate that real-world use of HEMO-SEAL sutures may be associated with reduced hemostat usage and costs, and reduced bleeding that requires additional hemostats and/or transfusions.

Traumastem Powder in Treatment of Non-Traumatic Anterior Epistaxis in Emergency Department; a Randomized Clinical Trial

It is concluded that Traumastem can conveniently control anterior epistaxis, but it is not successful in cases with severe bleeding.

Efficacy of oxidized regenerated cellulose combined with fibrin glue in reducing pulmonary air leakage after segmentectomy in a porcine lung model

A new method combining oxidized regenerated cellulose and fibrin glue to cover the intersegmental plane in clinical lung segmentectomy to prevent postoperative air leakage is designed, suggesting that ORC may be an effective alternative material to replace PGA sheet to combine with fibr in glue for preventing air leakage after segmentectomy.

Time-dependent effects of cellulose and gelatin-based hemostats on cellular processes of wound healing

It is concluded that GELA may be preferred over ORC and ONRC over short-, intermediateand long-term exposures, and alters protein levels of key mediating cytokines in fibroblasts.

Prospective, multicenter, randomized, controlled trial evaluating the performance of a novel combination powder vs hemostatic matrix in cardiothoracic operations

This trial compared the hemostatic performance of a novel combination powder (CP) to a control hemostatic matrix (HM) in cardiothoracic operations.

Comparison of the efficacy of five standard topical hemostats: a study in porcine liver and spleen models of surgical bleeding

The hemostatic efficacy of Cutanplast Standard and Fast gelatin sponge and powder and Emosist oxidized regenerated cellulose (ORC) gauze in porcine liver and spleen surgical bleeding models is investigated to find out whether these products are suitable for surgical applications involving parenchymal organ bleeding.

References

SHOWING 1-10 OF 23 REFERENCES

Choice of Hemostatic Agent and Hospital Length of Stay in Cardiovascular Surgery

The purpose of this study was to compare the expected and actual LOS by HA in cardiac procedures and found that FLOSEAL was associated with less likelihood of exceeding expected LOS compared with baseline, and further assessment is warranted to distinguish products with favorable outcomes.

Impact of bleeding-related complications and/or blood product transfusions on hospital costs in inpatient surgical patients

This study characterizes the increased hospital LOS and cost associated with bleeding-related complications and/or transfusions occurring as a consequence of surgery, and supports implementation of blood-conservation strategies.

Patterns of use of hemostatic agents in patients undergoing major surgery.

An Essential Primer for Understanding the Role of Topical Hemostats, Surgical Sealants, and Adhesives for Maintaining Hemostasis

An understanding of the benefits and potential risks associated with these agents will allow hospital pharmacists to assist in the development and implementation of institutional policies regarding the safe and effective use of hemostatic agents commonly used in the surgical suite.

Fibrin sealant use for minimising peri-operative allogeneic blood transfusion.

The results suggest that fibrin sealants are efficacious in reducing both post-operative blood loss and peri-operative exposure to allogeneic RBC transfusion, and raises concerns about the use of blood transfusion practice as an outcome variable in trials of fibrIn sealant.

Evolution of hemostatic agents in surgical practice

The historical progress of topical hemostats into present day surgery and urology is reviewed and outlined, to highlight opportunities for future research.

Safety and hemostatic efficacy of fibrin pad in partial nephrectomy: Results of an open-label Phase I and a randomized, standard-of-care-controlled Phase I/II study

The first-in-man trial of fibrin pad demonstrated its safety and efficacy as an adjunctive hemostatic technique for mild-to-moderate bleeding in partial nephrectomy and suggested that the product should not replace sutures or meticulous surgical techniques for the treatment of severe arterial hemorrhage.